Abstract
The aim of this study is to evaluate the safety and effectiveness of rapid clozapine titration in patients with schizophrenia in hospital settings. We conducted a retrospective two-center cohort study to compare the safety and effectiveness of clozapine with different titration rates in treatment-refractory patients with schizophrenia. In the first center, clozapine was started at 25–50 mg followed by 50–100 mg as needed every 6 h on day 1, followed by increases of 50–100 mg/day. In the second center, titration was slower; clozapine initiated with 12.5–50 mg on day 1 followed by increases of 25–50 mg/day. The number of days between starting of clozapine until discharge was shorter in the rapid titration group (22.4 ± 8.72 vs 27.0 ± 10.5, p = 0.1). Number of days of total hospital stay were significantly shorter in the rapid titration group (29.6 ± 10.6 vs 41.2 ± 14.8, p = 0.002). Hypotension was more common in the rapid titration group and one patient had suspected myocarditis. Rapid clozapine titration appeared safe and effective. The length of stay following initiation of clozapine was shorter in the rapid-titration group, although this was not statistically significant. However starting clozapine earlier together with rapid titration has significantly shortened the length of hospital stay in patients with treatment refractory schizophrenia.
Similar content being viewed by others
References
Meltzer HY: Clozapine: Balancing safety with superior antipsychotic efficacy. Clinical Schizophrenia & Related Psychoses 6(3):134–144, 2012. doi:10.3371/CSRP.6.3.5.
Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine’s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. The American Journal of Psychiatry 156(7):990–999, 1999.
Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 17(2):247–261, 1991.
Sajatovic M, Meltzer HY: Clozapine-induced myoclonus and generalized seizures. Biological Psychiatry 39(5):367–370, 1996. doi:10.1016/0006-3223(95)00499-8.
Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P: Rapid clozapine titration in treatment-refractory bipolar disorder. Journal of Affective Disorders 166:168–172, 2014. doi:10.1016/j.jad.2014.04.020.
Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. The Australian and New Zealand Journal of Psychiatry 46(9):816–825, 2012. doi:10.1177/0004867412438871.
Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P: Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatrica Scandinavica 130(1):25–29, 2014. doi:10.1111/acps.12241.
APA: Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC, American Psychiatric Association; 2000.
Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ: Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study. Schizophrenia Research 141(2–3):173–178, 2012. doi:10.1016/j.schres.2012.08.018.
Kilian JG, Kerr K, Lawrence C, Celermajer DS: Myocarditis and cardiomyopathy associated with clozapine. Lancet 354(9193):1841–1845, 1999.
Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L et al.: Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Safety 30(1):47–57, 2007.
Merrill DB, Dec GW, Goff DC: Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology 25(1):32–41, 2005.
Nielsen J, Correll CU, Manu P, Kane JM: Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? The Journal of Clinical Psychiatry 74(6):603–613; quiz 13, 2013. doi:10.4088/JCP.12r08064.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Funding
This research received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.
Rights and permissions
About this article
Cite this article
Poyraz, C.A., Özdemir, A., Sağlam, N.G.U. et al. Rapid Clozapine Titration in Patients with Treatment Refractory Schizophrenia. Psychiatr Q 87, 315–322 (2016). https://doi.org/10.1007/s11126-015-9394-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-015-9394-y